SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Active filters
Keyword
All time
Results for " NMIBC " 1 found 🔀 AI-powered Shuffle
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed p